KRAS codon 12 and 13 mutations in metastatic colorectal cancer: Predictive marker in first-line bevacizumab-based chemotherapy

被引：0
|
作者：
Cunha Pereira, T. [1 ]
Salgueiro, F. [1 ]
Monteiro, A. [1 ]
Felix Soares, R. [1 ]
Macedo, F. [1 ]
Jacinto, P. [1 ]
Paulo, J. [1 ]
Bonito, N. [1 ]
Marques, M. [1 ]
Ribeiro, J. [1 ]
Sousa, G. [1 ]
机构：
[1] Portuguese Oncol Inst Coimbra Francisco Gentil, Coimbra, Portugal
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.307
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-225
引用
收藏
页码：S163 / S164
页数：2
相关论文
共 50 条
  • [31] Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
    Tejpar, Sabine
    Celik, Ilhan
    Schlichting, Michael
    Sartorius, Ute
    Bokemeyer, Carsten
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3570 - 3577
  • [32] Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab
    Tejpar, S.
    Bokemeyer, C.
    Celik, I.
    Schlichting, M.
    Sartorius, U.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer
    Vaidyanathan, Gayatri
    Groman, Adrienne
    Wilding, Gregory
    Fakih, Marwan G.
    ONCOLOGY, 2010, 79 (1-2) : 67 - 71
  • [34] Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis
    Hu, W.
    Xu, W. -S.
    Liao, X. -F.
    He, H. -J.
    MINERVA CHIRURGICA, 2015, 70 (06) : 451 - 458
  • [35] Cost-effectiveness analysis of the addition of bevacizumab to first-line chemotherapy in metastatic colorectal cancer
    Villa, D.
    Hedden, L.
    Peacock, S.
    Kennecke, H. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study
    Diaz-Rubio, Eduardo
    Gomez-Espana, Auxiliadora
    Massuti, Bartomeu
    Sastre, Javier
    Reboredo, Margarita
    Luis Manzano, Jose
    Rivera, Fernando
    Jose Safont, Ma
    Montagut, Clara
    Gonzalez, Encarnacion
    Benavides, Manuel
    Marcuello, Eugenio
    Cervantes, Andres
    Martinez de Prado, Purificacion
    Fernandez-Martos, Carlos
    Arrivi, Antonio
    Bando, Inmaculada
    Aranda, Enrique
    PLOS ONE, 2012, 7 (10):
  • [37] Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab
    Bousahba, A.
    Behourah, Z.
    ANNALS OF ONCOLOGY, 2019, 30
  • [38] Predictive value of VEGF gene polymorphisms in metastatic colorectal cancer patients treated with a bevacizumab-based chemotherapy.
    Ulivi, Paola
    Marisi, Giorgia
    Scarpi, Emanuela
    Passardi, Alessandro
    Ragazzini, Angela
    Frassineti, Giovanni Luca
    Zoli, Wainer
    Valgiusti, Martina
    Nanni, Oriana
    Calistri, Daniele
    Casacci, Fabio
    Amadori, Dino
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations
    Liang, Yi-Hsin
    Lin, Yu-Lin
    Liau, Jau-Yu
    Tsai, Jia-Huei
    Liang, Jin-Tung
    Lin, Been-Ren
    Hung, Ji-Shiang
    Tseng, Li-Hui
    Lin, Liang-In
    Chang, Yih-Leong
    Cheng, Ann-Lii
    Yeh, Kun-Huei
    ANTICANCER RESEARCH, 2015, 35 (07) : 4207 - 4214
  • [40] Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
    Scartozzi, M.
    Giampieri, R.
    Maccaroni, E.
    Del Prete, M.
    Faloppi, L.
    Bianconi, M.
    Galizia, E.
    Loretelli, C.
    Belvederesi, L.
    Bittoni, A.
    Cascinu, S.
    BRITISH JOURNAL OF CANCER, 2012, 106 (05) : 799 - 804
12345